Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
A phase I-II study of treatment of metastatic melanoma using induction therapy with
Biochemotherapy plus Bevacizumab followed by consolidation therapy with Ipilimumab (BBI).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
California Pacific Medical Center Research Institute